The ABCD Semaglutide (Ozempic) audit launched in 2019 to capture real-world outcomes in the UK. Pooled analysis from the SUSTAIN trials has demonstrated similar HbA1c and weight reducing efficacy in older populations compared younger. We report the impact of age on weight and HbA1c response to semaglutide.
Methods: Routinely collected clinical data was entered by participating centres into a secure online tool and included provided baseline and follow-up data were available. Age groups at commencement were defined as <40years, 40-64.9 years and ≥65years. Changes between baseline and follow-up were assessed using multivariate regression analysis to correct for potential confounders, with Bonferroni corrections for multiple comparisons. Analysis performed in Stata 16.
Results: In total 1,623 individuals (49.9% female) were included with baseline mean±SD age 58.9±11.0 years, HbA1c 9.4±1.7% and 107.1±23.5kg. Over a median follow-up of 0.7 years (IQR 0.4-1.0), HbA1c reduced by 1.2% (95%CI 1.1-1.3, P<0.001) and weight reduced by 4.7kg (95%CI 4.1-5.3, P<0.001). Baseline HbA1c levels were similar across age groups, but baseline weight was significantly lower with increasing age (mean±SD youngest group 115.5±28.6 vs. 101.8±19.5 in the oldest group, P<0.001). In those aged <40years HbA1c fell by 1.4% (95% 0.9-1.9) and weight reduced by 4.4kg (1.4-7.4); in age 40-64.9years HbA1c fell by 1.2% (1.0-1.3) and weight by 4.3kg (3.7-5.0) and in age ≥65years HbA1c reduced by 1.2% (1.0-1.4) and weight by 4.7kg (3.8-5.6) (P<0.001 for all). No significant differences between groups were noted for either change in HbA1c or weight.
Conclusions: Semaglutide is associated with HbA1c reductions across all ages. Weight reductions are also similar despite differences in baseline weight; this may be variably desirable in older individuals where weight maintenance may be preferred to prevent frailty.
T.S.J. Crabtree: Speaker's Bureau; Abbott, Novo Nordisk, Dexcom, Inc., Sanofi, Insulet Corporation, Lilly Diabetes. K. Adamson: Speaker's Bureau; Lilly Diabetes. A. Bickerton: None. A. Evans: None. S.M. Phillips: None. A. Gallagher: None. D. Barnes: None. K. Dhatariya: Other Relationship; AstraZeneca, Menarini, Boehringer-Ingelheim, Abbott Diagnostics, Eli Lilly and Company, Novo Nordisk. B.C.T. Field: Speaker's Bureau; AstraZeneca, Boehringer-Ingelheim, Eli Lilly and Company, Novo Nordisk, Sanofi. Consultant; Tape Specialities Limited. I.R. Idris: None. R.E. Ryder: Speaker's Bureau; Abbott, Besins Healtcare, BioQuest, GI Dynamics. Consultant; GI Dynamics. Other Relationship; Novo Nordisk.
Funded by ABCD
